Chinese stocks - watch CMED

[chinaman711]

Watch CMED if it gets thru 26 CYD slow long term play at 6.23 PACT good l/t play imo and of course my favorite XING for the long term.

[chinaman711]

CMED thru 26 and volume picking up a little. This 1 can run if volume comes in, resistance at 26.61 good luck

[chinaman711]

CMED thru 27 on its way to 30 imo. Cramer hates this 1 so it will probally go to 40 : )

[chinaman711]

CYD having a nice day at 6.48 needs some volume to get it moving.

[optimus25]

CMED thru 27 on its way to 30 imo. Cramer hates this 1 so it will probally go to 40 : )

Cramer didn't mind it when it was in the 30's last year. I actually think he was recommending it in the mid 30's before the fallout.

Nice move today though, not sure what the catalyst was this morning.

[stockviper]

NWD has started running again the last few days. It bottomed out around 1.50 a few weeks agao and recently been bumping up almost every day and is is now back over 1.70.

[ub3rn00ber]

CYD having a nice day at 6.48 needs some volume to get it moving.

BOOOOOOOOOOOO
AND THEN
BOOOOO
AND THEN

DOH!!!

sold yesterday at the low of the day.

[chinaman711]

CYD looking good again today imo it will see 7 next week and may run back to 9 plus. CMED another great day too as volume is starting to come in as the 30 day avg. has been 495k and it could do that in the 1st hour or so. Good luck

[chinaman711]

CMED looks like it might take off

[chinaman711]

CMED reports after the close today. CYD nice earnings report out this morning and XING looking like a good day too. Singapore, November 13, 2006 - China Yuchai International Limited (“CYI”) today announced a net income of Rmb41.5 million (US$5.2 million) for the quarter ended September 30, 2006 as compared to a net income of Rmb31.6 million (US$3.8 million) for the same period in 2005.
Net sales of Rmb1,401.3 million (US$177.2 million) for the quarter ended September 30, 2006 achieved by Guangxi Yuchai Machinery Company Limited (“Yuchai”), the key operating subsidiary of CYI, represent an increase of 30% compared to Rmb1,074.3 million (US$130.4 million) for the same period last year. Total unit sales of 56,154 diesel engines for the quarter ended September 30, 2006 were 28% higher than the 43,773 units sold for the same period last year. This increase in net sales was primarily attributable to higher demand for light-duty and industrial diesel engines.
Net sales of Rmb5,030.8 million (US$636.1 million) for the nine months ended September 30, 2006 represent an increase of approximately 10% compared to Rmb4,589.7 million (US$557.3 million) for the same period last year. Total unit sales of 213,297 diesel engines for the nine months ended September 30, 2006 was approximately 17% higher than the 182,287 unit sales for the same period last year. This was mainly due to the strong unit sales arising from Yuchai’s 4-series light-duty diesel and industrial engines.
The overall gross margin of 20.2% for the nine months ended September 30, 2006 was lower than the 24.1% gross margin for the same period in 2005, due to keen competition, product sales mix and higher raw material costs. Yuchai sold 45% more of the lower margin light-duty diesel engines in the first nine months of 2006 compared to the same period in 2005.
The increase in research and development costs is mainly due to higher expenditure relating to Yuchai’s engine development on Euro III and IV compliant engines.
For the nine months ended September 30, 2006, selling, general and administrative expenses were comparable to the same period in 2005.

[chinaman711]

CASS watch this 1 another chinese stock that has had huge runs in the past.

[chinaman711]

CYD looks like it could see 7 today, CAAS could see 10 tomorrow imo

[chinaman711]

CAAS up 2 bucks looking real good and may see that 10 today if this keeps up.

[chinaman711]

CAAS very nice

[chinaman711]

CMED nice earnings report see if we can get thru 29 tomorrow---------Second Quarter Unaudited Financial Results for the Fiscal Year Ending March 31, 2007
Monday November 13, 4:00 pm ET


BEIJING--(BUSINESS WIRE)--China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED - News), a leading China-based medical device company that develops, manufactures and markets tumor therapy systems and advanced in-vitro diagnostic systems, today announced its unaudited financial results for the second quarter of 2006 ("2Q FY2006"). The Company's 2006 fiscal year ends March 31, 2007, which makes the quarter ended September 30, 2006, the Company's second quarter.
2Q FY2006 Highlights

Net revenues increased by 49.2% year-over-year to RMB131.4 million (US$16.6 million).
Net income increased by 67.0% year-over-year to RMB71.6 million (US$9.1 million).
Diluted earnings per ADS* were RMB2.62 (US$0.33) for the quarter.
*1 ADS = 10 ordinary shares

"We had a very solid quarter, and we were happy to see the continued growth in our business," commented Mr. Xiaodong Wu, Chairman and Chief Executive Officer of China Medical. "In our ECLIA business, our results were particularly strong, with revenues increasing 79.1% compared to the equivalent quarter last year and 20.1% compared to the first quarter of this fiscal year. In October, we released an upgraded version of our semi-automatic system and we think this will help sustain the growth of our diagnostic business. Additionally, we have also recently completed the development of two HIV diagnostic reagents and are now waiting for approval from the State Food and Drug Administration of China ("SFDA") to start selling the products. We aim to broaden our reagent offering to a total of 70 kits within the next 12 months, which will make us one of the leading providers of chemiluminescence immunoassay reagents in the industry worldwide"

Financial Results

China Medical reported net revenues of RMB131.4 million (US$16.6 million) for the 2Q FY2006, representing a 49.2% increase from corresponding period in 2005 and a 44.5% increase from the previous quarter.

The Company's revenues are generated from two product lines, HIFU tumor therapy systems and ECLIA diagnostic systems. ECLIA system sales include sales of ECLIA analyzers and reagent kits.

HIFU tumor therapy system sales for the 2Q FY2006 were RMB80.0 million (US$10.1 million), representing a 34.7% increase from the corresponding period in 2005 and a 66.3% increase from the previous quarter. The year-over-year growth in this sector was primarily driven by an increase in unit sales resulting from an increased level of awareness and acceptance of the HIFU tumor therapy system in the medical community in China. A slight price increase in September 2006 also contributed to revenue growth. The sequential quarter growth was primarily due to the seasonality in sales of this medical device. Historically, sales of HIFU units start to pick up after the June quarter every year when hospitals in China become active again in procuring large capital equipment.

ECLIA system sales for the 2Q FY2006 were RMB 51.4 million (US$6.5 million), representing a 79.1% increase from the corresponding period in 2005 and a 20.1% increase from the previous quarter. Both the year-over-year and sequential growth in the ECLIA system sales reflects rapid acceptance of the ECLIA technology in the medical community in China and lead to an increase in sales of reagent kits. The addition of the new reagent kits over the last 12 months from 27 to 56 broadened the Company's reagent portfolio, which in turn helped to drive sales of analyzers.

Gross margin increased to 71.9% as compared to 69.8% and 70.7% for the corresponding quarter in 2005 and previous quarter, respectively. This improvement in gross margin is primarily due to the price increase that was passed through for the Company's HIFU tumor therapy system and a higher revenue contribution from ECLIA reagents.

Research and development expenses were RMB8.4 million (US$1.1million), representing a significant year-over-year increase and a 42.9% sequential increase primarily due to a medical study conducted in partnership with the Ministry of Health of China (the "MOH") and pre-clinical trials conducted in the United States. The MOH initiative focuses on the clinical benefits of the Company's HIFU tumor therapy system used in combination with conventional cancer treatment. The U.S. pre-clinical trials are part of the process to obtain regulatory approval for the Company's HIFU therapy system in the United States.

Sales and marketing expenses were RMB4.5 million (US$0.6 million), representing a 13.8% year-over-year increase and a 7.1% sequential increase primarily due to promotional activities for the Company's products.

General and administrative expenses were RMB12.0 million (US$1.5 million), representing a 74.3% year-over-year increase and a 4.3% sequential increase primarily due to an increase in headcount as the Company expanded its operations and public company expenses incurred after the Company's listing in August 2005.

Interest income was RMB8.0 million (US$1.0 million), representing a significant increase from the corresponding period in 2005 but only a 2.9% increase from the previous quarter. The year-over-year increase was primarily due to interest income generated from the net proceeds received from the Company's initial public offering in August 2005.

Other income was RMB1.1 million (US$0.1 million), which related to the government grant to support the Company's development of ECLIA products.

Income tax expense was RMB7.0 million (US$0.9 million). Despite a substantial increase in taxable income, the income tax expense decreased slightly from the corresponding period in 2005. This decrease was a result of an income tax concession granted by the PRC tax authorities in February 2006. The income tax rate for the Company's PRC subsidiary was reduced from 15% to 10% starting retrospectively in January 2005 and ending in December 2007. As a result of the tax concession, the Company changed the tax rate used to record its income tax expense. The estimated effective tax rate for 2Q FY2006 was 8.9%, which is close to 9.1% from the previous quarter.

Net income was RMB71.6 million (US$9.1 million), representing a 67.0% increase from the corresponding period in 2005 and a 56.0% increase from the previous quarter.

As of September 30, 2006, China Medical's cash balance was RMB937.2 million (US$118.6 million). Net operating cash flow and capital expenditures for the 2Q FY2006 were RMB86.4 million (US$10.9 million) and RMB12.1 million (US$1.5 million), respectively. The increase in capital expenditures was mainly related to the construction of additional manufacturing facilities to meet the increased market demand for reagent kits.

For the convenience of readers, certain RMB amounts have been translated into U.S. dollars at the rate of RMB7.9040 to US$1.00, the noon buying rate in the City of New York for cable transfers of RMB per U.S. dollar as certified for customs purposes by the Federal Reserve Bank of New York, as of Friday, September 29, 2006

[MGNiko]

Is it too late to enter CAAS or CMED?

[sealatte]

CAAS up 2 bucks looking real good and may see that 10 today if this keeps up.

chinaman.. nice pick..... should move up....

[chinaman711]

CAAS and CYD great day yesterday CMED not too bad either. Keep your eye on CYD if it gets thru 9 as this 1 has alot more to go imo. Hope to see XING pick up on this chinese action, XING needs to get thru 14.60 and any news should get it going again. Same with PACT not action yet and it is another cheap chinese stock and a good long term play imo. CMED traded 30.50 last night in after hours and this 1 looks like a good long term play too but it has had a huge run from 19 so be careful with it. Good luck